Structural basis of a shared antibody response to SARS-CoV-2
Open accessPublished version of a preprint
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Molecular understanding of neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could accelerate vaccine design and drug discovery. We analyzed 294 anti-SARS-CoV-2 antibodies and found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein. Co-crystal structures of two IGHV3-53-neutralizing antibodies with RBD, with or without Fab CR3022, at 2.33- to 3.20-angstrom resolution revealed that the germline-encoded residues dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site. This binding mode limits the IGHV3-53 antibodies to short complementarity-determining region H3 loops but accommodates light-chain diversity. These IGHV3-53 antibodies show minimal affinity maturation and high potency, which is promising for vaccine design. Knowledge of these structural motifs and binding mode should facilitate the design of antigens that elicit this type of neutralizing response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of public antibody responses have been reported for SARS-CoV-2, principal among these being VH3–53/VH3–66 and VH1–58 (VH3–30 is also found, but the antibodies are not potent neutralizers) (Yuan et al., 2020; Barnes et al., 2020; Dejnirattisai et al., 2021).”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Their engagement with the RBD is dictated by CDR-H1 and CDR-H2, while the CDR-H3 is characteristically short and makes rather few interactions”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Cited by
Items 401–500 of 597
Production of native recombinant proteins using a novel split intein affinity technology
Clifford, R., Lindman, S., Zhu, J., Luo, E., Delmar, J. A., Tao, Y., Ren, K., Lara, A., Cayatte, C., McTamney, P. M., et al. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.464908 · Cited by 8
Tan, Z., Yang, C., Lin, P., Ramadan, S., Yang, W., Rashidi, Z., Lang, S., Shafieichaharberoud, F., Gao, J., Pan, X., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302755 · Cited by 8
Stäb, S., Pearce, N. M., Tronrud, D. E., Ginn, H. M., Fadda, E., Santoni, G., & Thorn, A. (2024) · Crystallography Reviews · doi:10.1080/0889311x.2024.2363756 · Cited by 7
“The original wild-type SARS-CoV-2 strain elicited a strong V3-53 (variable gene) sequence response [227,272] which was not seen against the Beta variant (Table 4), which moderately favoured antibodies with V4-39 sequence [273].”
Alshahrani, M., Parikh, V., Foley, B., & Verkhivker, G. M. (2025) · Viruses · doi:10.3390/v17060741 · Cited by 8
de Souza, A. S., de Souza, R. F., & Guzzo, C. R. (2023) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-023-00534-0 · Cited by 7
“The small rectangle is located at the S1 subunit while the big rectangle is located at the S2 subunit 1 3 RBD, they do not prevent interaction with hACE2 but desta-bilize the homotrimer [91, 92].”
BackgroundThe D Gene in CDR H3 Determines a Public Class of Human Antibodies to SARS-CoV-2
Yuan, M., & Wilson, I. A. (2024) · Vaccines · doi:10.3390/vaccines12050467 · Cited by 9
“We and others have reported several public antibody classes elicited by the ancestral viral infection or vaccination against SARS-CoV-2, e.g., public antibodies encoded by IGHV3-53/3-66 [2,3] and IGHV1-58/IGKV3-20 [4].”
BackgroundCastro, A., Öztürk, K., Zanetti, M., & Carter, H. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246731 · Cited by 8
Public Immunity: Evolutionary Spandrels for Pathway-Amplifying Protective Antibodies
Sangesland, M., & Lingwood, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708882 · Cited by 7
Ueno, M., Iwata‐Yoshikawa, N., Matsunaga, A., Okamura, T., Saito, S., Ashida, S., Yoshida, I., Nagashima, M., Asakura, H., Yaoita, Y., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105297 · Cited by 7
“, 2020), but it has been reported that RBD-specific neutralizing antibodies isolated during early convalescence have low levels of somatic hypermutations (Barnes et al., 2020b; Robbiani et al., 2020; Yuan et al., 2020), which accumulate in SARS-CoV-2 antibodies in the months after infection (Gaebler et al.”
Kulemzin, S., Sergeeva, M., Baranov, K., Gorchakov, A., Guselnikov, S., Belovezhets, T. N., Volkova, O., Najakshin, A., Chikaev, N., Danilenko, D., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060895 · Cited by 6
“having a short CDRH3 ranging 9–13 amino acid residues share a described or a predicted mechanism of S binding mediated by the germline residues of CDRH1 and CDRH2 [12,13].”
BackgroundInfluentialWilliams, A. H., & Zhan, C. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c02123 · Cited by 8
AIRRscape: An interactive tool for exploring B-cell receptor repertoires and antibody responses
Waltari, E., Nafees, S., Wong, J., McCutcheon, K. M., & Pak, J. E. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010052 · Cited by 8
Boer, J. C., Pan, Q., Holien, J. K., Nguyen, T., Ascher, D. B., & Plebanski, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954435 · Cited by 7
Qualitative monitoring of SARS-CoV-2 mRNA vaccination in humans using droplet microfluidics
Broketa, M., Sokal, A., Mor, M., Canales-Herrerías, P., Perima, A., Meola, A., Fernández, I., Iannascoli, B., Chenon, G., Vandenberghe, A., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.166602 · Cited by 10
Qiang, M., Ma, P., Li, Y., Liu, H., Harding, A. C., Min, C., Liu, L., Yuan, M., Ji, Q., Tao, P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.06.370676 · Cited by 7
“We previously reported that 161 IGHV3-53 antibodies from convalescent patients, with minimal SHM and high potency, 162 have two key germline motifs in CDRH1 and CDRH2 that are primarily used for 163 recognition of SARS-CoV-2 S-RBD, namely 32NY33 and 53SGGS56 (31, 32).”
BackgroundSARS-CoV-2 receptor binding mutations and antibody mediated immunityPreprint
Mejdani, M., Haddadi, K., Pham, C., & Mahadevan, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.25.427846 · Cited by 7
Schepens, B., van Schie, L., Nerinckx, W., Roose, K., Breedam, W. V., Fijałkowska, D., Devos, S., Weyts, W., Cae, S. D., Vanmarcke, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.08.433449 · Cited by 7
Wang, Y., Lv, H., Lei, R., Yeung, Y.-H., Shen, I. R., Choi, D., Teo, Q. W., Tan, T. J. C., Gopal, A. B., Chen, X., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.11.557288 · Cited by 7
“Our prediction was based on seven specificity categories, namely influenza HA head, influenza HA stem, HIV, SARS-CoV-2 S NTD, SARS-CoV-2 S RBD, SARS-CoV-2 S S2, and others (none of the above).”
InfluentialRegulators and Conductors of Immunity: Natural Immune System in Health and Autoimmunity
Böröcz, K., Szinger, D., Simon, D., Berki, T., & Németh, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115413 · Cited by 9
Chen, X., Li, L., Du, R., Wang, Z., Li, Y., Sun, Y., Qin, R., Feng, H., Hu, L., Chen, X., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115964 · Cited by 6
Parkinson, J., Hard, R. L., Ko, Y. S., & Wang, W. (2025) · Advanced Science · doi:10.1002/advs.202504350 · Cited by 9
Sangesland, M., Li, N., Tsybovsky, Y., Rodgers, M. D., Han, J., Rodriguez, A. J., Ferguson, J. A., Henry, A. R., Smith, S. D., Roberts-Torres, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ady3570 · Cited by 6
Cofas‐Vargas, L. F., Mendoza-Espinosa, P., Montalvo-Sandoval, F. D., Rodriguez, S. P., Rauda-Ceja, J. A., Hernández‐Peralta, P., Durán-Vargas, A., Trujillo‐Roldán, M. A., Valdez‐Cruz, N. A., & García‐Hernández, E. (2025) · mAbs · doi:10.1080/19420862.2025.2575083 · Cited by 8
Feng, Z., Sang, Z., Xiang, Y., Escalera, A., Weshler, A., Schneidman‐Duhovny, D., García‐Sastre, A., & Shi, Y. (2025) · Cell Systems · doi:10.1016/j.cels.2025.101452 · Cited by 8
Chuang, G., Shen, C., Cheung, C. S., Gorman, J., Creanga, A., Joyce, M. G., Leung, K., Rawi, R., Wang, L., Yang, E. S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662909 · Cited by 6
Germline-encoded specificities and the predictability of the B cell response
Vieira, M. C., Palm, A.-K. E., Stamper, C. T., Tepora, M. E., Nguyen, K. D., Pham, T. D., Boyd, S. D., Wilson, P. C., & Cobey, S. E. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011603 · Cited by 6
Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron
Patel, A. B., Kumar, S., Lai, L., Keen, M. M., Valanparambil, R. M., Chennareddy, C., Laughlin, Z. T., Frank, F., Cheedarla, N., Verkerke, H., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113150 · Cited by 7
Engelbrecht, E., Rodriguez, O. L., & Watson, C. T. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400131 · Cited by 6
Physical-Chemical Regulation of Membrane Receptors Dynamics in Viral Invasion and Immune Defense
Qin, R., An, C., & Chen, W. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167800 · Cited by 6
“(RBD and N-terminal domains of S1 subunit) to an ACE2-binding fusion-competent state and thus may increase viral infectivity.(89) Our group further found that mechanical force extent almost fourtime longer lifetimes of SARS2-S-D614G binding with ACE2 receptors and 35 times faster forceinduced S1/S2 detachment than tho…”
Pang, S., Boopathi, V., Murugesan, M., Mathiyalagan, R., Ahn, J., Xiaolin, C., Yang, D., Kwak, G.-Y., Kong, B. M., Yang, D., et al. (2022) · Natural Product Communications · doi:10.1177/1934578x221134331 · Cited by 6
Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak
Maciorowski, D., Ogaugwu, C., Durvasula, S. R., Durvasula, R. V., & Kunamneni, A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220979579 · Cited by 6
Rey, F. A. (2021) · Comptes Rendus Biologies · doi:10.5802/crbiol.53 · Cited by 11
Lunderberg, J. M., Dutta, S., Collier, A.-R. Y., Lee, J.-S., Hsu, Y., Wang, Q., Zheng, W., Hao, S., Zhang, H., Feng, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032574 · Cited by 7
Ku, M.-W., Bourgine, M., Authié, P., Lopez, J., Nemirov, K., Moncoq, F., Noirat, A., Vesin, B., Névo, F., Blanc, C., et al. (2020) · bioRxiv · doi:10.1101/2020.07.21.214049 · Cited by 7
“…alone (LV::S1), (ii) S1-S2 ectodomain, without the transmembrane and C-terminal short internal tail (LV::S1-S2), and (iii) full-length, membrane anchored form of S (LV::SFL), which all harbor the RBD (Figure 1A, Figure S1), albeit with potential conformational heterogeneities (Yuan et al., 2020).”
BackgroundEhling, R. A., Weber, C. R., Mason, D. M., Friedensohn, S., Wagner, B., Bieberich, F., Kapetanovic, E., Vazquez-Lombardi, R., Roberto, R. B. D., Hong, K.-L., et al. (2021) · bioRxiv · doi:10.1101/2021.02.12.430940 · Cited by 5
mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5Preprint
Andreano, E., Paciello, I., Pierleoni, G., Maccari, G., Antonelli, G., Abbiento, V., Pileri, P., Benincasa, L., Giglioli, G., Piccini, G., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.04.502828 · Cited by 6
High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spikePreprint
Tan, T. J. C., Mou, Z., Lei, R., Ouyang, W. O., Yuan, M., Song, G., Andrabi, R., Wilson, I. A., Kieffer, C., Dai, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.24.509341 · Cited by 6
Feng, Y., Yuan, M., Powers, J. M., Hu, M., Munt, J. E., Arunachalam, P. S., Leist, S. R., Bellusci, L., Adams, L. E., Sundaramurthy, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.19.524784 · Cited by 6
“3A. 25F9 targets one side of the RBD with some overlap with the conserved CR3022 site (Fig.”
BackgroundInfluentialA novel plasma proteomic‐based model for predicting liver fibrosis in HIV/HBV co‐infected adults
Yuan, R., Zhang, Y.-X., Deng, L.-P., Yu, X.-X., Zhuang, K., Chen, X.-P., Cao, Q., Ping, H., Ke, H.-N., Gui, X., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28222 · Cited by 6
Saini, S., Pareekh, S., & Kumar, Y. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2222174 · Cited by 5
“Moreover, due to the loose definition of epitopes, all summaries of epitopes predicted by EpiPred and experimental epitopes recognised on WT RBD were loaded as input (Yuan et al., 2020).”
BackgroundVerkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031646 · Cited by 6
“The expanding body 72 of structural and biochemical studies of the SARS-CoV-2 S complexes with different classes of 73 potent antibodies targeting distinct binding epitopes of the S-RBD as well as various antibody 74 cocktails and combinations have revealed multiple conformation-dependent epitopes, highlighting 75 the…”
BackgroundThe molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
Tolbert, W. D., Chen, Y., Sun, L., Benlarbi, M., Ding, S., Manickam, R., Pangaro, E., Nguyen, D. N. P., Gottumukkala, S., Côté, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1178355 · Cited by 4
“Indeed when examples of VH 3-53 encoded SARS-CoV-2 neutralizing antibodies with longer CDR H3s were determined, many were found to bind the RBD differently (12).”
BackgroundInfluentialStructures and functions of the limited natural polyclonal antibody response to parvovirus infection
Adu, O. F., Lee, H., Früh, S. P., Schoenle, M. V., Weichert, W. S., Flyak, A. I., Hafenstein, S. L., & Parrish, C. R. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2423460122 · Cited by 7
Dhawan, M. K., Thakur, N., Sharma, M. K., & Rabaan, A. A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117936 · Cited by 7
Structure and Antigenicity of Kaposi's Sarcoma‐Associated Herpesvirus Glycoprotein B
Fang, X., Sun, C., Xie, C., Cheng, B., Lu, Z., Zhao, G., Sui, S., Zeng, M., & Liu, Z. (2025) · Advanced Science · doi:10.1002/advs.202502231 · Cited by 5
Bergasa-Caceres, F., & RABITZ, H. A. (2021) · COVID · doi:10.3390/covid1010023 · Cited by 5
Potential of conserved antigenic sites in development of universal SARS-like coronavirus vaccines
Wang, S., Wu, D., Xiong, H., Wang, J., Tang, Z., Chen, Z., Wang, Y., Zhang, Y., Dong, Y., Lin, X. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952650 · Cited by 7
Untangling associations between immunoglobulin genotypes, repertoires and function
Dopico, X. C., Mandolesi, M., & Hedestam, G. B. K. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.05.003 · Cited by 5
Striking Similarities between CDRs in Some mAbs That Neutralize COVID-19
Mi, T., & Burgess, K. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00409 · Cited by 5
Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2Preprint
Ragonnet‐Cronin, M., Nutalai, R., Huo, J., Dijokaite-Guraliuc, A., Das, R., Tuekprakhon, A., Supasa, P., Liu, C., Selvaraj, M., Groves, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.14.500063 · Cited by 5
Mouse-adapted SARS-CoV-2 Omicron BA.5 infection induces post-acute lung fibrosis in BALB/c mice
Powers, J. M., Leist, S. R., Suryadevara, N., Zost, S. J., Binshtein, E., Abdelgadir, A., Mallory, M. L., Edwards, C. E., Gully, K. L., Hubbard, M. L., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01406-25 · Cited by 8
Memory B cell development in response to mRNA SARS-CoV-2 and nanoparticle immunization in mice
Wiatr, M., wang, Z., Canis, M., Hernandez, B., Gazumyan, A., Santos, G. S. S., Shawraz, S., lee, S., Bieniasz, P. D., Hatziioannou, T., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2527869123 · Cited by 4
“Memory antibodies elicited after the initial mRNA prime and boost in humans typically target Class 1 and 2 epitopes that overlap with the ACE2 binding site of the RBD (51, 54).”
Zheng, Y., Wang, S., Zhou, X., Qiao, S., Zhao, X., Chen, Y., Li, Z., Li, Z., Sun, X., Tan, S., et al. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.05.038 · Cited by 6
Aiello, A., Ruggieri, S., Navarra, A., Tortorella, C., Vanini, V., Haggiag, S., Prosperini, L., Cuzzi, G., Salmi, A., Quartuccio, M. E., et al. (2024) · Vaccines · doi:10.3390/vaccines12080926 · Cited by 4
“Anti-RBD antibodies can be directed against different epitopes in the RBD of the spike protein, but not all of them can neutralize the infectious capacity of the virus [57].”
BackgroundYoon, E.-H., Kim, D., Jeon, H., Kwon, Y., Jang, Y., Kim, S., & Hwang, K. Y. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.043 · Cited by 4
“These antibodies mainly encode VH genes, such as IGHV3-53, IGHV3-66, IGHV1-58, IGHV3-30, and IGHV3-30–3.”
Milon, T. I., Sarkar, T., Chen, Y., Grider, J. M., Chen, F., Ji, J., Jois, S. D. S., Kousoulas, K. G., Raghavan, V. V., & Xu, W. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1395374 · Cited by 5
Adhikari, N., Amin, S. A., & Jha, T. (2020) · Methods in pharmacology and toxicology · doi:10.1007/7653_2020_46 · Cited by 7
Poeschla, E. M. (2020) · eLife · doi:10.7554/elife.64496 · Cited by 4
Fujii, T., Hagihara, M., Mitamura, K., Nakashima, S., Ohara, S., Uchida, T., Inoue, M., Okuda, M., Yasuhara, A., Murakami, J., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9209-21 · Cited by 4
Neutralizing Antibody Response to Sarbecovirus Is Delayed in Sequential Heterologous Immunization
Lv, H., So, R. T. Y., Teo, Q. W., Yuan, M., Liu, H., Lee, C.-C. D., Yip, G. K., Ng, W. W., Wilson, I. A., Peiris, M. J. S., et al. (2022) · Viruses · doi:10.3390/v14071382 · Cited by 4
“1) was codon optimized and cloned into the phCMV3 vector [21].”
MethodResultB cell receptor repertoire analysis from autopsy samples of COVID-19 patients
Iwabuchi, S., Tsukahara, T., Okayama, T., Kitabatake, M., Motobayashi, H., Shichino, S., Imafuku, T., Yamaji, K., Miyamoto, K., Tamura, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1034978 · Cited by 5
“IGHV1-69 and IGHV3-23 were among the top 7 and 10 antibodies detected, respectively, and some of the BCR heavy chains detected in the lung lobe were also frequently detected (9, 12).”
BackgroundEmbong, A. K., Nguyen, P. Q. T., Wang, J., Kanagaiah, P., Chaves, F. A., Fitzgerald, T. F., Zhou, Q., Kosoy, G., Branche, A. R., Miller, B. L., et al. (2022) · Pathogens · doi:10.3390/pathogens11020186 · Cited by 4
B cell maturation restored ancestral germlines to control Omicron BA.2.86Preprint
Paciello, I., Pierleoni, G., Pantano, E., Antonelli, G., Pileri, P., Maccari, G., Cardamone, D., Realini, G., Perrone, F., Neto, M. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.03.583187 · Cited by 4
Optimizing the breadth of SARS-CoV-2-neutralizing antibodies in vivo and in silico
Kuroda, D., Moriyama, S., Sasaki, H., & Takahashi, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2526873 · Cited by 4
“IGHV3-53/66 antibodies have several distinct features 34,42 : (1) They often possess a shorter CDR-H3 (≤10, Kabat/Chothia definitions), which potentially results in a geometrically flat paratope.”
Affinity maturation and light-chain-mediated paratope diversification anticipates viral evolution
Dingus, J. G., Yoo, D. K., Kumar, S., Wang, Y., Kibria, M. G., Saghaei, S., Allahyari, Z., Chen, J. W., Caputo, N., Hwang, J., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116800 · Cited by 4
“9–11 IGHV3-53/66 antibodies bind a functionally restricted epitope on SARS-CoV-2 receptor binding domain (RBD) with extensive overlap with the binding site for ACE2, 9,12 the receptor required for viral entry into host cells.”
Major classes of neutralizing antibodies evaded by the SARS-CoV-2 Omicron variant
Yuan, M., & Wilson, I. A. (2023) · Structure · doi:10.1016/j.str.2023.06.005 · Cited by 3
Larsen, D. N., Kaczmarek, J. Z., Palarasah, Y., Graversen, J. H., & Højrup, P. (2024) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2024.141011 · Cited by 3
Hu, Y., Hu, C., Wang, S., Ren, L., Hao, Y., Wang, Z., Liu, Y., Su, J., Zhu, B., Li, D., et al. (2024) · Pathogens · doi:10.3390/pathogens13040272 · Cited by 3
Lee, H. (2021) · Advanced Theory and Simulations · doi:10.1002/adts.202100012 · Cited by 2
Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments
Abdurrahman, L., Fang, X., & Zhang, Y. (2021) · Current Molecular Medicine · doi:10.2174/1566524021666211013121831 · Cited by 4
Sequence and functional characterization of a public HIV-specific antibody clonotype
Murji, A. A., Raju, N., Qin, J. S., Kaldine, H., Janowska, K., Fechter, E. F., Mapengo, R. E., Scheepers, C., Setliff, I., Acharya, P., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103564 · Cited by 6
“Public antibody sequences have become an important research direction for a variety of diseases, including dengue, influenza, HIV-1, and SARS-CoV-2 (Parameswaran et al., 2013; Jackson et al., 2014; Setliff et al., 2018; Yuan et al., 2020).”
BackgroundDou, Y., Xu, K., Deng, Y., Jia, Z., Lan, J., Xu, X., Zhang, G., Cao, T.-S., Liu, P., Wang, X., et al. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad002 · Cited by 4
“IGHV3–53 has been shown to be the most frequently used germline gene for targeting SARS-CoV-2 RBD [18].”
BackgroundRatswohl, C., García, C. V., Ahmad, A., Gonschior, H., Lebedin, M. Y., Silvis, C. E., Spatt, L., Gerhard, C., Lehmann, M., Sander, L. E., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202350408 · Cited by 3
“1 IgG [79], 7CDI for P2C-1F11 IgG [25], 6M0J for human ACE2 [80], 1HZH for a human IgG1 antibody [81], as well as 6WPS and 7KJ5 for SARS-CoV-2 spike WT [71, 82].”
Discovery of neutralizing SARS-CoV-2 antibodies enriched in a unique antigen specific B cell cluster
Nielsen, S. S. F., Barnkob, N. M., Hansen, R. W., Bansia, H., Vestergaard, M., Rothemejer, F. H., Worsaae, A., Brown, D., Pedersen, M. L., Rahimic, A. H. F., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291131 · Cited by 3
“Curiously, otherwise reported IGHV3-66 and IGHV3-53 that are associated with class I neutralizing mAbs most commonly seen in convalescent individuals [19, 24–26], were used in only 1.74% and 1.17% of the isolated cells, respectively [27–29].”
InfluentialChen, X., Mohapatra, A., Nguyen, H. T. V., Schimanski, L. M., Tan, T. K., Rijal, P., Chen, C., Cheng, S., Lee, W.-H., Chou, Y., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012246 · Cited by 3
Karyagina, A. S., Gromov, A. V., Grunina, T. M., Lyaschuk, A. M., Av, G., Strukova, N. V., Generalova, M. S., Galushkina, Z. M., Soboleva, L. A., Dobrinina, O. Y., et al. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921100096 · Cited by 3
Broadly neutralizing antibodies against SARS-CoV-2 variants
Zhang, L. (2022) · National Science Open · doi:10.1360/nso/20220005 · Cited by 3
Evidence of antigenic imprinting in sequential Sarbecovirus immunizationPreprint
Lv, H., So, R. T. Y., Yuan, M., Liu, H., Lee, C.-C. D., Yip, G. K., Ng, W. W., Wilson, I. A., Peiris, M. J. S., Wu, N. C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.14.339465 · Cited by 3
Bullen, G., Galson, J., Villar, P., Moreels, L., Ledsgaard, L., Mattiuzzo, G., Hall, G., Bentley, E., Masters, E. W., Tang, D. M., et al. (2020) · bioRxiv · doi:10.1101/2020.12.29.424711 · Cited by 4
Wilson, P. C., Changrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M. A., Rehrauer, W. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-678247/v1 · Cited by 3
Chen, E. C., Gilchuk, P., Zost, S. J., Ilinykh, P. A., Binshtein, E., Huang, K., Myers, L., Bonissone, S. R., Day, S., Kona, C. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.12.476089 · Cited by 3
Xiong, H., Sun, H., Wang, S., Yuan, L., Liu, L., Zhu, Y., Zhang, J., Huang, Y., Qi, R., Jiang, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1386044/v1 · Cited by 3
B cells imprinted by ancestral SARS-CoV-2 develop pan-sarbecovirus neutralization in immune recallsPreprint
Chen, X., Li, L., Du, R., Wang, Z., Li, Y., Sun, Y., Qin, R., Feng, H., Hu, L., Chen, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.13.618110 · Cited by 4
Generation of antigen-specific paired chain antibody sequences using large language modelsPreprint
Wasdin, P. T., Johnson, N. V., Janke, A. K., Held, S., Marinov, T. M., Jordaan, G., Vandenabeele, L., Pantouli, F., Gillespie, R. A., Vukovich, M. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.20.629482 · Cited by 3
Yan, Q., Huang, X., Liu, B., Yao, Y., Zheng, H., Song, Y., Wu, F., He, Z., Li, S., Chen, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.10.693372 · Cited by 3
Mouse V(D)J Humanization Recapitulates human-like Severe SARS-CoV-2 Immune ImprintingPreprint
Niu, X., Jian, F., Li, Y. K., Li, K., Lei, S., Song, W., Kong, R., Cai, X. L., An, R., Wang, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.18.694353 · Cited by 4
“Enabled by the IGHV3-53/66 germline genes, which encode a prototypic public Class 1 antibody response targeting the ACE2-binding site 29 – 36 , Wuhan priming induces a high-frequency pool of these potent "masking" antibodies, the abundance of which scales directly with the intensity of the priming.”
Alshahrani, M., Parikh, V., Foley, B., & Verkhivker, G. M. (2025) · Biomolecules · doi:10.3390/biom15091340 · Cited by 3
“We perform structural binding epitope mapping and analysis of closely-related cross-reactive but weakly neutralizing Class 4 group F1 antibodies CR3022 [31,56,57], EY6A [57], and COVA1-16 [58].”
Enhanced Sampling Reveals Metastable Conformations Driving K417N-Mediated Class I Antibody Escape
Pan, X., Tadokoro, T., Onodera, T., Kita, S., Takahashi, Y., Maenaka, K., & Dokainish, H. M. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01396 · Cited by 2
Lv, N., Chen, P., Dai, X., Xu, H., Li, Z., Shan, Z., Li, J., Guo, F., Chen, Y., Li, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202517192 · Cited by 3
Conde, L., Oliveira, D. L., Maciel, G., Castro, F., Albuquerque, A., Rodrigues, D. A., Mello, Y., de Asis, G. M., Gabrielle, B., Ferreira, S. S., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf305 · Cited by 2
Huang, S., Wu, S., Li, F., Li, P., Sun, P., Cao, Y., Bao, H., Dong, K., Yang, J., Zhang, H., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1013893 · Cited by 2
Uneven TCR chain pairing constraints govern epitope recognition
Minervina, A. A., Pogorelyy, M. V., Mayer-Blackwell, K., Tirtakusuma, R., Schattgen, S., Fiore-Gartland, A. J., Walczak, A. M., Mora, T., Bradley, P. H., & Thomas, P. G. (2026) · Science · doi:10.1126/science.adx3863 · Cited by 4
Guerler, A., Baker, D., van den Beek, M., Gruening, B., Bouvier, D., Coraor, N., Shank, S. D., Zehr, J. D., Schatz, M. C., & Nekrutenko, A. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05389-8 · Cited by 2
“The corresponding PDB entries are 7C8V (Li, 2020), 6XC2 (Yuan, 2020), 6XC4 (Yuan, 2020), 7BZ5 (Wu, 2020) and 7C01 (Shi, 2020).”
A benchmark for evaluation of structure-based online tools for antibody-antigen binding affinity
Jiayi, X., Gong, J., Bo, X., Tong, Y., Ren, Z., & Ni, M. (2024) · Biophysical Chemistry · doi:10.1016/j.bpc.2024.107253 · Cited by 2
SARS-CoV-2: Prediction of critical ionic amino acid mutations
El-Assaad, A. M., & Hamieh, T. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108688 · Cited by 2
Wang, M., Liu, C., Fan, Q., Sun, Y., Tang, S., Guo, H., Zhou, B., Wang, H., Ge, X., Zhang, Z., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkae056 · Cited by 2
Fan, Q., Liu, C., Guo, H., Tang, S., Wang, H., Zhou, B., Sun, Y., Wang, M., Ge, X., Liu, L., et al. (2025) · Structure · doi:10.1016/j.str.2025.04.005 · Cited by 3
Banach, M., Harley, I. T. W., McCarthy, M. K., Rester, C., Stassinopoulos, A., Kedl, R. M., Morrison, T. E., & Cambier, J. C. (2022) · Magnetochemistry · doi:10.3390/magnetochemistry8020023 · Cited by 3
Fundamental aspects of the structural biology of coronaviruses
Lara-Hernández, I., Coronado-Ipiña, M. Á., Rocha-Rosas, K., & Comas‐García, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90248-9.00011-5 · Cited by 2
Host-Genome Similarity Characterizes the Adaption of SARS-CoV-2 to Humans
Sun, W. (2022) · Biomolecules · doi:10.3390/biom12070972 · Cited by 2
“In contrast, Omicron an interac with four antibody classes, uggesting an enhanced antibody escape breadth [59].”
BackgroundInfluential
Metadata
- Authors
- Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., Rogers, T. F., Landais, E., Sok, D., Jardine, J. G., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Wilson, Ian A.
- ORCID
- Venue
- Science
- Published
- 2020-08-28
- Volume
- 369
- Issue
- 6507
- Pages
- 1119-1123
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7402627
- OpenAlex
- W3041564586
- Cited by
- 589
- References
- 53
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 55 · 2023: 64 · 2022: 133 · 2021: 203 · 2020: 51
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by)
- Funders
- National Institutes of Health (K99 AI139445, UM1 AI44462)
- Bill and Melinda Gates Foundation (OPP1170236)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, neutralizing antibodies, receptor binding domain, spike protein, ACE2 binding site, co-crystal structure, germline antibodies, affinity maturation, vaccine design, antibody structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.